NCT00154375

Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma

Phase III Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 240 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase III study comparing Imatinib mesylate and hydroxyurea combination therapy with hydroxyurea monotherapy in patients with temozolomide resistant progressive glioblastoma.

Conditions

• Glioblastoma Multiforme
• Astrocytoma

Interventions

Type	Name	Description
DRUG	Imatinib mesylate	Imatinib was supplied as 100 mg and 400 mg tablets packaged in polyethylene bottles.
DRUG	Hydroxyurea

Timeline

• Start date: 2004-10-01
• Primary completion: 2008-08-01
• First posted: 2005-09-12
• Last updated: 2011-04-26
• Results posted: 2011-02-02

Locations

1 site across 1 country: Germany